-
- Construction
Teva invests in state-of-the-art biotech facility
Milestone for the medicine of tomorrow
It is a project of superlatives: The parent company of Ratiopharm, Teva, is investing around one billion US dollars at the Ulm site in biotechnological production. Starting in 2025, biopharmaceuticals will be produced in enormous bioreactors in the Ulm Danube Valley. These medicines are used for com…








